> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# New Study on Disclosures in Drug Ads
- URL: https://www.fdaweb.com/new-study-on-disclosures-in-drug-ads/
- Published: 2020-07-09T12:00:00.000Z
- Updated: 2026-09-14T16:20:39.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5147157

*Federal Register* notice: FDA is seeking comments on a new information collection entitled “Examination of Secondary Claim Disclosures and Biosimilar Disclosures in Prescription Drug Promotional Materials.” The proposed research will examine the impact of adding a disclosure about a secondary claim in DTC and healthcare professional-directed promotion in the context of a prescription drug Web site. It will also examine the effect of the presence of a comparative claim about the secondary claim. To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2020-07-07/pdf/2020-14514.pdf?ref=fdaweb.com).